How to buy Vaxart (VXRT) shares in Australia

Learn how to easily invest in Vaxart shares.

Vaxart Inc
NASDAQ: VXRT - USD
BIOTECHNOLOGY
$8.17
- $0.28 ( - 3.31%)

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Vaxart Inc is a biotechnology business with stocks listed in the US. Vaxart shares (VXRT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$8.17 – a decrease of 2.85% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Vaxart

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Vaxart. Find the share by name or ticker symbol: VXRT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vaxart reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$7.72, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Vaxart, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Vaxart. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Vaxart stock price (NASDAQ:VXRT)

Use our graph to track the performance of VXRT stocks over time.

Vaxart shares at a glance

Information last updated 2021-09-24.
52-week rangeUS$3.71 - US$15.8
50-day moving average US$8.6566
200-day moving average US$7.4433
Target priceUS$12.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) US$-0.476

Where to buy Vaxart stock

Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
US$0
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
US$0
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
US$0
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares
Australia’s lowest-cost broker for ASX shares and ETFs.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
Saxo Capital Markets (Classic account)
US$4
1%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Invest
US$0
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Vaxart stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Vaxart share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Considering buying Vaxart shares?

Before you consider Vaxart, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.

Show me how

Vaxart price performance over time

Historical closes compared with the last close of $8.17

1 week (2021-09-16) -0.61%
1 month (2021-08-26) -9.32%
3 months (2021-06-25) -4.33%
6 months (2021-03-26) 36.39%
1 year (2020-09-25) 10.41%
2 years (2019-09-26) 2,669.49%
3 years (2018-09-26) 187.68%
5 years (2016-09-26) -60.07%

Stocks similar to Vaxart

Vaxart financials

Revenue TTM US$1.2 million
Gross profit TTM US$-15,817,000
Return on assets TTM -22.69%
Return on equity TTM -45.05%
Profit margin 0%
Book value 1.627
Market capitalisation US$1 billion

TTM: trailing 12 months

Shorting Vaxart shares

There are currently 17.4 million Vaxart shares held short by investors – that's known as Vaxart's "short interest". This figure is 14.6% down from 20.3 million last month.

There are a few different ways that this level of interest in shorting Vaxart shares can be evaluated.

Vaxart's "short interest ratio" (SIR)

Vaxart's "short interest ratio" (SIR) is the quantity of Vaxart shares currently shorted divided by the average quantity of Vaxart shares traded daily (recently around 8.6 million). Vaxart's SIR currently stands at 2.02. In other words for every 100,000 Vaxart shares traded daily on the market, roughly 2020 shares are currently held short.

However Vaxart's short interest can also be evaluated against the total number of Vaxart shares, or, against the total number of tradable Vaxart shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaxart's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Vaxart shares in existence, roughly 140 shares are currently held short) or 0.1426% of the tradable shares (for every 100,000 tradable Vaxart shares, roughly 143 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vaxart.

Find out more about how you can short Vaxart stock.

Vaxart share dividends

We're not expecting Vaxart to pay a dividend over the next 12 months.

Have Vaxart's shares ever split?

Vaxart's shares were split on a 1:11 basis on 13 February 2018. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vaxart shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Vaxart shares which in turn could have impacted Vaxart's share price.

Vaxart share price volatility

Over the last 12 months, Vaxart's shares have ranged in value from as little as US$3.71 up to US$15.8. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaxart's is 0.3903. This would suggest that Vaxart's shares are less volatile than average (for this exchange).

Vaxart overview

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site